SCHEDULE 13G/A: Venrock Healthcare Entities Maintain 4.4% Stake in Astria Therapeutics, Inc. as of Year-End 2024
Amendment to Beneficial Ownership Report
A group of Venrock Healthcare entities and individuals have filed an amended Schedule 13G, confirming their collective beneficial ownership of 4.4% of Astria Therapeutics, Inc.'s common stock as of December 31, 2024.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 2,457,348 shares of Astria Therapeutics, Inc. Common Stock.
- This aggregate ownership represents 4.4% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 56,434,219 shares of Common Stock outstanding as of October 31, 2024, as reported in Astria Therapeutics, Inc.'s Quarterly Report on Form 10-Q filed on November 13, 2024.
- The ownership is distributed among the entities as follows: 435,520 shares by VHCP III, 43,561 shares by VHCP Co-Investment III, and 1,978,267 shares by VHCP EG.
- VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
- The securities were not acquired or held for the purpose of changing or influencing the control of Astria Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G/A) reporting beneficial ownership. It contains factual information about shareholdings and does not convey positive or negative sentiment regarding the issuer's performance or future prospects.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by a venture capital firm specializing in healthcare, indicating their continued passive investment in Astria Therapeutics, Inc., a biotechnology company. Such filings are common for institutional investors maintaining stakes in public companies.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Date as of which the number of outstanding shares of Astria Therapeutics, Inc. Common Stock (56,434,219 shares) was reported in the Issuer's Form 10-Q. |
| 2024-11-13 | Date Astria Therapeutics, Inc. filed its Quarterly Report on Form 10-Q with the SEC, reporting outstanding shares. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership as of this date). |
| 2025-02-14 | Date the Joint Filing Agreement was executed and the Schedule 13G/A was signed. |
Keywords
Astria Therapeutics Inc., Common Stock, Schedule 13G/A, Beneficial Ownership, Venrock Healthcare Capital Partners, VHCP, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.